Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
3-hydroxyisobutyrate dehydrogenase, mitochondrial (HIBADH), is a tetrameric enzyme located in the mitochondrial matrix that catalyzes the reversible NAD+-dependent oxidation of 3-hydroxyisobutyrate, an intermediate in the valine catabolic pathway, to methylmalonate semialdehyde[4][10][11]. This reaction supports the breakdown of branched-chain amino acids for cellular energy and metabolic homeostasis. HIBADH is highly specific for its substrate and exhibits high stereoselectivity in catalysis. In mammals, HIBADH is also present in spermatozoa, where it is implicated in mitochondrial function and sperm motility, potentially serving as a biomarker for sperm quality[12][13]. Mutations or deficiencies of HIBADH may disrupt normal amino acid metabolism, but there are no current therapies or drugs targeting this enzyme, nor are there recognized safety concerns associated with its function.
Not applicable (no approved drugs or investigational agents directly target HIBADH)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-hydroxyisobutyrate dehydrogenase, mitochondrial (HIBADH).